Key points are not available for this paper at this time.
The projected increase in the global probiotics market is driven by growing consumer awareness of gut health and the potential benefits of microbial supplements. However, the market currently exhibits a significant gap in probiotic yeast options, with Saccharomyces boulardii being the predominant probiotic yeast available. This limitation restricts diversity and potential tailored applications of alternative probiotic yeast strains. Pichia, a genus of yeast, has emerged as a promising candidate. This review explores the safety profile and probiotic attributes of Pichia strains, which collectively highlight its potential as an effective probiotic yeast. Evidence indicates that Pichia exhibits beneficial characteristics such as resilience in harsh gastrointestinal (GI) conditions, antimicrobial activity against pathogens, and immunomodulatory effects that could contribute to gut health. Additionally, the non-pathogenic nature of Pichia and its history of safe and wide use in food and beverage fermentation processes increases confidence in its safety for human consumption. Given its potential, Pichia may diversify the probiotic yeast market and present an alternative beneficial organism that may contribute to general health and well-being.
Samiksha et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: